Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to examine the effect of add-on therapy with the direct
renin inhibitor Aliskiren in comparison to placebo on renal blood flow in patients with heart
failure and reduced renal function.
- Primary outcome measure: change in renal blood flow at 6 months
- Secondary outcome measures: changes in renal function, N-terminal pro Brain natriuretic
peptide, left ventricular function, blood pressure and neurohormones